Santosh L Saraf

List of Publications by Citations

147 papers	1,289 citations	19 h-index	33 g-index
153 ext. papers	1,679 ext. citations	4 avg, IF	4.47 L-index

#	Paper	IF	Citations
147	Update on meningiomas. *Oncologist*, **2011**, 16, 1604-13	5.7	109
146	Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 441-8	4.7	84
145	Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. *British Journal of Haematology*, **2014**, 164, 729-39	4.5	75
144	COVID-19 infection in patients with sickle cell disease. *British Journal of Haematology*, **2020**, 189, 851-852	4.5	66
143	Differences in the clinical and genotypic presentation of sickle cell disease around the world. *Paediatric Respiratory Reviews*, **2014**, 15, 4-12	4.8	59
142	Feasibility of implementing a comprehensive warfarin pharmacogenetics service. *Pharmacotherapy*, **2013**, 33, 1156-64	5.8	57
141	Clinical effectiveness of decitabine in severe sickle cell disease. *British Journal of Haematology*, **2008**, 141, 126-9	4.5	56
140	Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 207-15	6.9	54
139	Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. *Leukemia and Lymphoma*, **2013**, 54, 1989-95	1.9	53
138	Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy. *Haematologica*, **2015**, 100, 1275-84	6.6	44
137	Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1759-1765	4.7	35
136	Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease. *Seminars in Hematology*, **2018**, 55, 87-93	4	34
135	APOL1, Ethalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia. *Haematologica*, **2017**, 102, e1-e6	6.6	28
134	Hyperfiltration is associated with the development of microalbuminuria in patients with sickle cell anemia. *American Journal of Hematology*, **2014**, 89, 1156-7	7.1	27
133	Hypoxic response contributes to altered gene expression and precapillary pulmonary hypertension in patients with sickle cell disease. *Circulation*, **2014**, 129, 1650-8	16.7	27
132	Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 2034-41	4.7	26
131	Characterization of opioid use in sickle cell disease. *Pharmacoepidemiology and Drug Safety*, **2018**, 27, 479-486	2.6	25

130	Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial. *American Journal of Hematology*, **2017**, 92, E520-E528	7.1	23
129	Comparison of patients from Nigeria and the USA highlights modifiable risk factors for sickle cell anemia complications. *Hemoglobin*, **2014**, 38, 236-43	0.6	21
128	Patterns of opioid use in sickle cell disease. *American Journal of Hematology*, **2016**, 91, 1102-1106	7.1	18
127	Association of circulating transcriptomic profiles with mortality in sickle cell disease. *Blood*, **2017**, 129, 3009-3016	2.2	14
126	Genetic polymorphism of APOB is associated with diabetes mellitus in sickle cell disease. *Human Genetics*, **2015**, 134, 895-904	6.3	14
125	Metabolomic Markers of Kidney Function Decline in Patients With Diabetes: Evidence From the Chronic Renal Insufficiency Cohort (CRIC) Study. *American Journal of Kidney Diseases*, **2020**, 76, 511-520	7.4	14
124	Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers. *Transfusion*, **2015**, 55, 864-74	2.9	13
123	Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study. *British Journal of Haematology*, **2018**, 182, 259-270	4.5	12
122	Hemolysis and hemolysis-related complications in females vs. males with sickle cell disease. *American Journal of Hematology*, **2018**, 93, E376-E380	7.1	11
121	Changes in Conjunctival Hemodynamics Predict Albuminuria in Sickle Cell Nephropathy. *American Journal of Nephrology*, **2015**, 41, 487-93	4.6	11
120	and acute kidney injury in sickle cell anemia. *Blood*, **2018**, 132, 1621-1625	2.2	11
119	Risk factors for vitamin D deficiency in sickle cell disease. *British Journal of Haematology*, **2018**, 181, 828-835	4.5	11
118	Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 350-7	2	10
117	Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study. *Blood Advances*, **2020**, 4, 1501-1511	7.8	10
116	Identification of ceruloplasmin as a biomarker of chronic kidney disease in urine of sickle cell disease patients by proteomic analysis. *American Journal of Hematology*, **2018**, 93, E45-E47	7.1	10
115	Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis. *British Journal of Haematology*, **2019**, 185, 116-127	4.5	9
114	Urinary orosomucoid is associated with progressive chronic kidney disease stage in patients with sickle cell anemia. *American Journal of Hematology*, **2018**, 93, E107-E109	7.1	9
113	Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. *British Journal of Haematology*, **2021**, 192, 761-768	4.5	9

112	Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease. *Blood Advances*, **2020**, 4, 1978-1986	7.8	8
111	Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease. *Pharmacotherapy*, **2020**, 40, 535-543	5.8	8
110	Progressive glomerular and tubular damage in sickle cell trait and sickle cell anemia mouse models. *Translational Research*, **2018**, 197, 1-11	11	8
109	Red blood cell alloimmunization in sickle cell disease: assessment of transfusion protocols during two time periods. *Transfusion*, **2018**, 58, 1588-1596	2.9	8
108	Associations of Ethalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts. *Blood Advances*, **2017**, 1, 693-698	7.8	8
107	FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease. *Blood*, **2020**, 136, 19-20	2.2	8
106	A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant. *Bone Marrow Transplantation*, **2018**, 53, 300-306	4.4	7
105	Use of anti-inflammatory analgesics in sickle-cell disease. *Journal of Clinical Pharmacy and Therapeutics*, **2017**, 42, 656-660	2.2	7
104	Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease. *British Journal of Haematology*, **2011**, 153, 386-92	4.5	7
103	Fixed Low-Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Anemia in Nigeria. *American Journal of Hematology*, **2018**, 93, E193	7.1	7
102	Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center. *Pharmacotherapy*, **2016**, 36, 1166-1172	5.8	6
101	Safety of chronic transdermal fentanyl use in patients receiving hemodialysis. *American Journal of Health-System Pharmacy*, **2016**, 73, 947-8	2.2	6
100	Conjunctival microvascular hemodynamics following vaso-occlusive crisis in sickle cell disease. *Clinical Hemorheology and Microcirculation*, **2015**, 62, 359-67	2.5	6
99	"Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia. *American Journal of Hematology*, **2019**, 94, E112-E115	7.1	5
98	Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease. *PLoS ONE*, **2020**, 15, e0229710	3.7	5
97	Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease. *Pharmacotherapy*, **2020**, 40, 525-534	5.8	5
96	Comparing the Effectiveness of Education Versus Digital Cognitive Behavioral Therapy for Adults With Sickle Cell Disease: Protocol for the Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications (CaRISMA) Study. *JMIR Research Protocols*, **2021**, 10, e29014	2	5
95	Health-Related Quality of Life and Personal Life Goals of Adults With Sickle Cell Disease After Hematopoietic Stem Cell Transplantation. *Western Journal of Nursing Research*, **2019**, 41, 555-575	2	5

94	Program expansion of a day hospital dedicated to manage sickle cell pain. *American Journal of Hematology*, **2018**, 93, E20-E21	7.1	5
93	Erythropoiesis-stimulating agents in sickle cell anaemia. *British Journal of Haematology*, **2018**, 182, 602-605	4.5	5
92	Anemia and Incident End-Stage Kidney Disease. *Kidney360*, **2020**, 1, 623-630	1.8	4
91	The experience of adults with sickle cell disease and their HLA-matched adult sibling donors after allogeneic hematopoietic stem cell transplantation. *Journal of Advanced Nursing*, **2019**, 75, 2943-2951	3.1	4
90	The morbidity and mortality of end stage renal disease in sickle cell disease. *American Journal of Hematology*, **2019**, 94, E138-E141	7.1	4
89	A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease. *Human Molecular Genetics*, **2016**, 25, 4601-4609	5.6	3
88	Kidney ultrasound findings according to kidney function in sickle cell anemia. *American Journal of Hematology*, **2019**, 94, E288-E291	7.1	3
87	Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease. *Journal of Clinical Medicine*, **2019**, 8,	5.1	3
86	Chronic Opioid Use Pattern in Adult Patients with Sickle Cell Disease. *Blood*, **2015**, 126, 3400-3400	2.2	3
85	Low Fixed Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Disease in Nigeria. *Blood*, **2017**, 130, 981-981	2.2	3
84	Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects. *Blood*, **2019**, 134, 616-616	2.2	3
83	Engulfment and cell motility 1 (ELMO1) and apolipoprotein A1 (APOA1) as candidate genes for sickle cell nephropathy. *British Journal of Haematology*, **2021**, 193, 628-632	4.5	3
82	Potential Contribution of Pulmonary Thromboembolic Disease in Pulmonary Hypertension in Sickle Cell Disease. *Annals of the American Thoracic Society*, **2020**, 17, 899-901	4.7	2
81	Heme A1M@d at the kidney in sickle cell disease. *Blood*, **2020**, 135, 979-981	2.2	2
80	ARTS: automated randomization of multiple traits for study design. *Bioinformatics*, **2014**, 30, 1637-9	7.2	2
79	Phase 1 Evaluation of Oral Tetrahydrouridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease. *Blood*, **2016**, 128, 124-124	2.2	2
78	Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis. *Haematologica*, **2021**, 106, 1749-1753	6.6	2
77	Association of Blood Pressure Genetic Risk Score with Cardiovascular Disease and CKD Progression: Findings from the CRIC Study.. *Kidney360*, **2021**, 2, 1251-1260	1.8	2

76	Race/ethnicity and underlying disease influences hematopoietic stem/progenitor cell mobilization response: A single center experience. *Journal of Clinical Apheresis*, **2021**, 36, 634-644	3.2	2
75	Use of metformin in patients with sickle cell disease. *American Journal of Hematology*, **2019**, 94, E13-E15	7.1	2
74	Reply to Ruan X et al: "A comment on pattern of opioid use in sickle cell disease". *American Journal of Hematology*, **2017**, 92, E43	7.1	1
73	Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways. *Haematologica*, **2017**, 102, e282-e284	6.6	1
72	The Effect of Crizanlizumab on the Number of Days Requiring Opioid Use for Management of Pain Associated with Vaso-Occlusive Crises in Patients with Sickle Cell Disease: Results from the Sustain Trial. *Blood*, **2020**, 136, 32-33	2.2	1
71	Health Care Utilization in Transplanted Versus Non-Transplanted Sickle Cell Disease Patients. *Blood* , **2018**, 132, 313-313	2.2	1
70	Regulatory Genetic Variation at the S100B Gene Associates with Vaso-Occlusive Manifestations in Sickle Cell Disease. *Blood*, **2018**, 132, 1063-1063	2.2	1
69	Type 2 Diabetes Mellitus in Patients with Sickle Cell Disease: A Population-Based Longitudinal Analysis of Three Cohorts. *Blood*, **2018**, 132, 4817-4817	2.2	1
68	Thrombomodulin and Endothelial Dysfunction in Sickle Cell Anemia. *Blood*, **2019**, 134, 3558-3558	2.2	1
67	Non-p53 Dependent, Leukemia Initiating-Cell Selective, Therapy.. *Blood*, **2009**, 114, 2077-2077	2.2	1
66	Hydroxyurea for Treatment of Sickle Cell Disease in Adults in Africa. *Blood*, **2016**, 128, 1305-1305	2.2	1
65	Urinary Ceruloplasmin Concentration Predicts Development of Kidney Disease in Sickle Cell Disease Patients. *Blood*, **2016**, 128, 4865-4865	2.2	1
64	Antimicrobial resistance is a risk factor for mortality in adults with sickle cell disease. *Haematologica*, **2021**, 106, 1745-1748	6.6	1
63	Biomarkers of Cardiopulmonary, Renal, and Liver Dysfunction in an Adult Sickle Cell Disease Cohort. *Blood*, **2019**, 134, 3574-3574	2.2	1
62	A Multi-Center, Phase-2 Trial of Losartan for the Nephropathy of Sickle Cell Anemia. *Blood*, **2016**, 128, 265-265	2.2	1
61	Role of Ethnicity in Clinical Outcomes of Patients with Ph-Negative Myeloproliferative Neoplasms. *Blood*, **2012**, 120, 2076-2076	2.2	1
60	S100B has pleiotropic effects on vaso-occlusive manifestations in sickle cell disease. *American Journal of Hematology*, **2020**, 95, E62-E65	7.1	1
59	Chronic opioid use can be reduced or discontinued after haematopoietic stem cell transplantation for sickle cell disease. *British Journal of Haematology*, **2020**, 191, e70-e72	4.5	1

58	Biomarkers of clinical severity in treated and untreated sickle cell disease: a comparison by genotypes of a single center cohort and African Americans in the NHANES study. *British Journal of Haematology*, **2021**, 194, 767-778	4.5	1
57	Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. *Kidney International*, **2021**, 100, 1292-1302	9.9	1
56	Utility of the revised cardiac risk index for predicting postsurgical morbidity in Hb SC and Hb S-thalassemia sickle cell disease. *American Journal of Hematology*, **2016**, 91, E316-7	7.1	1
55	High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease. *American Journal of Hematology*, **2019**, 94, E5-E7	7.1	1
54	Effects of Renin-Angiotensin Blockade and on Kidney Function in Sickle Cell Disease. *EJHaem*, **2021**, 2, 483-484	0.9	1
53	Use of Multiple Urinary Biomarkers for Early Detection of Chronic Kidney Disease in Sickle Cell Anemia Patients. *Blood*, **2020**, 136, 30-30	2.2	0
52	Hyperkalemia and Metabolic Acidosis Occur at Higher Estimated Glomerular Filtration Rates in Sickle Cell Disease. *Kidney360*,10.34067/KID.0006802021	1.8	0
51	Manifestations of Reduced Kidney Function Occur at a Higher Estimated Glomerular Filtration Rate in Sickle Cell Anemia. *Blood*, **2019**, 134, 2268-2268	2.2	0
50	Urinary Kringle Domain-Containing Protein HGFL: A Validated Biomarker of Early Sickle Cell Anemia-Associated Kidney Disease. *American Journal of Nephrology*, **2021**, 52, 582-587	4.6	0
49	Voxelotor and albuminuria in adults with sickle cell anaemia.. *British Journal of Haematology*, **2022**,	4.5	0
48	Laparoscopic Sleeve Gastrectomy in Sickle Cell Disease: a Case Series. *Obesity Surgery*, **2019**, 29, 3762-3764	3.7	
47	Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner et al. *British Journal of Haematology*, **2019**, 186, 782-783	4.5	
46	Cancer Incidence and Chemotherapy Tolerance in Patients with Sickle Cell Disease. *Blood*, **2020**, 136, 24-25	2.2	
45	Effects of Hydroxyurea and Renin-Angiotensin Blockade on Kidney Function in Sickle Cell Disease. *Blood*, **2020**, 136, 21-22	2.2	
44	Mass-Spectrometry Analysis of Urinary Biomarkers of Endothelial Injury in Sickle Cell Anemia Patients. *Blood*, **2020**, 136, 28-29	2.2	
43	Lower Apache II Score and Exchange Transfusions Predict Better Outcomes in the Intensive Care Unit for Patients with Sickle Cell Disease. *Blood*, **2020**, 136, 18-19	2.2	
42	Correction of Point-of-Care International Normalized Ratio (INR) Values in Patients with Sickle Cell Disease. *Blood*, **2020**, 136, 34-35	2.2	
41	Biomarker Association with Hypertension in Mild Versus Severe Sickle Cell Disease Genotypes of a Single Center Cohort, in Comparison with African Americans from the Nhanes Study. *Blood*, **2021**, 138, 2051-2051	2.2	

40	The Burden of Atrial Fibrillation in Sickle Cell Disease. *Blood*, **2021**, 138, 3119-3119	2.2
39	HIF-Mediated and Non-HIF-Mediated Differential Gene Expressions in Sickle Cell Reticulocyte and Their Impact on Clinical Manifestations. *Blood*, **2021**, 138, 950-950	2.2
38	Naloxone Use for Opioid Reversal in Patients with Sickle Cell Disease. *Blood*, **2021**, 138, 2038-2038	2.2
37	African American Patients with Multiple Myeloma Have Prolonged Responses after Autologous Stem Cell Transplantation.. *Blood*, **2005**, 106, 3131-3131	2.2
36	Quantitative Proteomics Identify Urinary Hgfl Protein As a Potential Marker for the Development of Chronic Kidney Disease in Sickle Cell Disease Patients. *Blood*, **2017**, 130, 967-967	2.2
35	Pulmonary Function Abnormalities in Adults with Sickle Cell Anemia. *Blood*, **2018**, 132, 3664-3664	2.2
34	Role of Automated Red Cell Exchange in Acute and Chronic Complications of Sickle Cell Disease. *Blood*, **2018**, 132, 3674-3674	2.2
33	Clinical, Laboratory, and Genetic Risk Factors for Thrombosis in Sickle Cell Disease. *Blood*, **2018**, 132, 9-9	2.2
32	Cancer Incidence in Sickle Cell Disease:an Institutional Experience. *Blood*, **2018**, 132, 1087-1087	2.2
31	Kidney Ultrasound Findings in Sickle Cell Anemia According to Kidney Disease and the APOL1 G1/G2 Risk Variants. *Blood*, **2018**, 132, 3663-3663	2.2
30	Association of Inpatient Opioid Utilization and Readmission Risk in Sickle Cell Disease. *Blood*, **2018**, 132, 4699-4699	2.2
29	Maximum Tolerated Dose Versus Fixed Low-Dose Hydroxyurea for Treatment of Adults with Sickle Cell Anemia - Retrospective Comparison of Two Studies. *Blood*, **2018**, 132, 3656-3656	2.2
28	A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients. *Blood*, **2018**, 132, 5218-5218	2.2
27	Progression of Albuminuria in Sickle Cell Anemia: A Multicenter, Longitudinal Study. *Blood*, **2019**, 134, 1004-1004	2.2
26	Risk Factors for Kidney Disease in Hb SC and Hb S⊞-Thalassemia Sickle Cell Disease. *Blood*, **2019**, 134, 2299-2299	2.2
25	Impact of Intravenous Opioid Shortage on Managing Pain Crisis in Sickle Cell Disease. *Blood*, **2019**, 134, 3390-3390	2.2
24	LINAC-based intensity modulated total marrow irradiation (TMI) in addition to myeloablative fludarabine/IV busulfan conditioning prior to allogeneic stem cell transplant for high-risk hematologic malignancies: A phase I study.. *Journal of Clinical Oncology*, **2014**, 32, 7045-7045	2.2
23	Utility of the Revised Cardiac Index Score for Predicting Post-Surgical Outcome in Hb SC or SBeta+ -Thalassemia Sickle Cell Disease. *Blood*, **2015**, 126, 3413-3413	2.2

22	Assessment of Bone Marrow Function in Sickle Cell Anaemia Patients Using Corrected Reticulocyte Counts. *Blood*, **2015**, 126, 4581-4581	2.2
21	CCN2 - Exploring a New Biomarker in Myelofibrosis. *Blood*, **2015**, 126, 4063-4063	2.2
20	Allogeneic Hematopoietic Cell Transplant in Sickle Cell Disease **2016**, 89-96	
19	Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Kidney Function in Patients with Sickle Cell Disease. *Blood*, **2016**, 128, 3666-3666	2.2
18	Elevated Levels of Hgfl Protein in Sickle Cell Disease Urine Samples That Induce Glomerular Permeability. *Blood*, **2016**, 128, 4841-4841	2.2
17	Genetic Modifiers Identify a High Risk Group for Stroke in Three Independent Cohorts of Sickle Cell Anemia Patients. *Blood*, **2016**, 128, 1015-1015	2.2
16	Progressive Glomerular Damage in Sickle Cell Trait and Sickle Cell Anemia Mouse Models. *Blood*, **2016**, 128, 3637-3637	2.2
15	Significance of, and Difficulty in Diagnosing, Erythropoietin Deficiency in Sickle Cell Anemia. *Blood*, **2008**, 112, 2479-2479	2.2
14	Favorable Responses to Novel Agents for Multiple Myeloma in African American Patients,. *Blood*, **2011**, 118, 4213-4213	2.2
13	Conjunctival Biopsy to Guide Treatment of Chronic Ocular Gvhd. *Blood*, **2012**, 120, 4491-4491	2.2
12	Clinical and Laboratory Predictors for Renal Damage in Sickle Cell Disease. *Blood*, **2012**, 120, 3252-3252	2.2
11	Hemoglobinuria Is a Risk Factor For Kidney Disease Progression In Sickle Cell Anemia. *Blood*, **2013**, 122, 996-996	2.2
10	Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intentsity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study. *Blood*, **2013**, 122, 3285-3285	2.2
9	Evaluation of point-of-care International Normalized Ratio in sickle cell disease. *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, e12533	5.1
8	The vasculopathic cord between pre-eclampsia and kidney function in sickle cell disease. *British Journal of Haematology*, **2021**, 194, 947-949	4.5
7	Using machine learning to predict rapid decline of kidney function in sickle cell anemia. *EJHaem*, **2021**, 2, 257-260	0.9
6	COVID-19 thromboembolism incidence, risk factors, and anticoagulation practices from a Chicago metropolitan US population.. *American Journal of Hematology*, **2022**,	7.1
5	Thrombomodulin and multiorgan failure in sickle cell anemia.. *American Journal of Hematology*, **2021**,	7.1

4 Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease **2020**, 15, e0229710

3 Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease **2020**, 15, e0229710

2 Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease **2020**, 15, e0229710

1 Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease **2020**, 15, e0229710